LUND (SWEDEN) – Immunovia AB (publ) today announced that the Annual Report for 2021 has been published.
The annual report can be downloaded in pdf format and is available on Immunovia’s website: https://investor.immunovia.com/financial-reports/.
For more information, please contact:
Senior Director Investor Relations and Corporate Communications
Tel: +46 736 36 35 74
This is information that Immunovia AB (publ) is obliged to make public pursuant to the Securities Market Act. The information was submitted for publication at 16:45 CET on March 10, 2022.
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
Annual report (PDF)